Is NMN legal in the US supplement market, how does it compare with NR, what human trials found, and what a month costs at the dose those trials used.
Researched from published studies and manufacturer specifications, checked .
We have not tested products ourselves. How we researchNMN is lawful to sell as a US dietary supplement: the FDA reversed its 2022 exclusion in September 2025. Human trials show it raises blood NAD+ and is well tolerated, but benefits on strength, glucose and other outcomes are mixed or small. NR has similar mixed results. Neither is shown to extend life.
Talk to your doctor first. This is general information, not medical advice. Supplements and devices can interact with medicines and health conditions. We quote study protocols for context and do not recommend doses.
As an Amazon Associate, Longevity Intel earns from qualifying purchases. Some links are affiliate links; we may earn a commission at no extra cost to you. Commissions never change what we write. How we make money
Double Wood · $48.95 (Double Wood's site, 29 Sept 2026)
Price as of July 2026. Check the retailer for the current price and availability.
Pros
Cons
Affiliate link · we may earn a commission
ChromaDex · $49 for 30 servings (brand site, 29 Sept 2026)
Price as of July 2026. Check the retailer for the current price and availability.
Pros
Cons
Affiliate link · we may earn a commission
The short answer: NMN is lawful to sell as a US dietary supplement: the FDA reversed its 2022 exclusion on 29 September 2025. Human trials show NMN raises blood NAD+ and is well tolerated over weeks to months, but the benefits on strength, glucose and other outcomes are small or mixed, and nothing shows it extends life. NR (nicotinamide riboside), the other popular NAD+ precursor, has similar mixed results and no head-to-head trial against NMN that we could find. Talk to your doctor before starting either.
Short version: yes, as a US dietary supplement since FDA’s 29 September 2025 letter, which reversed the November 2022 position. The dates below come from the public regulations.gov dockets: titles and posting dates are read from the regulations.gov API, and where the trade bodies are the only source for a date, that is marked.
| Date | What happened | Source |
|---|---|---|
| 2017 | NMN first sold as a US supplement, according to a regulatory tracker | PolicyCanary (secondary) |
| 13 Jun and 29 Jul 2022 | Companies file new dietary ingredient (NDI) notifications for NMN, including Willy Nutra (NDI 1234), SyncoZymes (1240, 1247) | Docket FDA-2022-S-0023 |
| Oct and Nov 2022 | FDA tells the notifiers NMN is excluded from the supplement definition because it was authorised for drug investigation first; the supplemental response to NDI 1259 (Inner Mongolia Kingdomway) is posted 8 Nov 2022 | FDA-2022-S-0023-0052; NPA calls this the “2022 determination” |
| 9 Mar 2023 | Citizen petition from the Natural Products Association and Alliance for Natural Health USA posted to docket FDA-2023-P-0872; NPA and others give the filing date as 7 Mar | FDA-2023-P-0872-0001 |
| 13 Mar 2023 | Amazon removes NMN supplements, per a tracker (not confirmed at Amazon) | PolicyCanary (secondary) |
| 30 Aug 2023 | FDA posts an interim response letter (no decision yet) | FDA-2023-P-0872-2022 |
| 28 Aug 2024 | NPA sues FDA in federal court, per a tracker | PolicyCanary (secondary) |
| 23 Dec 2024 | NPA files an amended petition (posted 2 Jan 2025) | FDA-2023-P-0872-2749 |
| 29 Sept 2025 | Two FDA letters dated this day answer the NPA/ANH petition and a separate Council for Responsible Nutrition petition (docket FDA-2023-P-1867). FDA concludes NMN is not excluded from the dietary supplement definition, citing evidence it was marketed as a supplement (as early as 2017) before its drug authorisation. The NPA/ANH response is FDA-2023-P-0872-2754; the docket labels it a partial approval and denial | Venable; NPA; National Law Review |
| Oct 2025 | NMN returns to Amazon, per a tracker | PolicyCanary (secondary) |
| 2 Dec 2025 (posted 9 Dec) | FDA reinstatement letters to the NDI notifiers: SyncoZymes (NDI 1240, letter dated 2 Dec per NPA), Willy Nutra (1234) and Inner Mongolia Kingdomway (1259) | -0067, -0066, -0069 |
| Late Dec 2025 | NPA voluntarily dismisses its lawsuit without prejudice; the NPA release says it filed the dismissal after FDA’s September response | NPA; date from PolicyCanary |
What it means for a buyer. FDA does not approve supplements or their claims, and NMN is still a new dietary ingredient: Venable notes firms must meet notification requirements and cannot rely on self-affirmed GRAS status to skip them. So “lawful” means a company can sell it as a supplement, not that FDA has checked a given bottle. A named third-party certifier on the label and a lot-specific certificate of analysis are the checks a buyer can make; see third-party testing explained. Rules differ outside the US: check your own regulator. Older pages that call NMN “banned” describe the 2022 to 2025 period. We found nothing from FDA after December 2025; FDA’s ingredient information page, updated 1 May 2026, did not surface an NMN entry. The text of the letters is blocked to our reader (403), so what each letter says rests on the dockets’ titles and on the NPA and Venable accounts, with the FDA links above for you to read.
Grades follow the rubric. Doses are what the trial used, not a recommendation.
| Attribute | NMN | NR |
|---|---|---|
| Grade | Emerging | Weak to Emerging |
| Raises NAD+ measures in blood | Yes: Igarashi 2022 (250 mg/day, older men, 6 or 12 weeks) and Yi 2023 (80 adults, 300, 600 or 900 mg/day for 60 days, highest at 600 and 900) | Reported consistently in reviews |
| Functional signals | Igarashi: only nominal gains in gait speed and left grip, no change in body composition. Yi: longer six-minute walk and better blood biological-age readout vs placebo, no HOMA-IR change. Yoshino 2021: better muscle insulin sensitivity in postmenopausal women with prediabetes (250 mg/day, 10 weeks) | Dollerup 2019: no effect on glucose tolerance or insulin in men with obesity (2,000 mg/day, 12 weeks) |
| Other | Yi authors declare employment at Abinopharm and ABA Chemicals; Yoshino’s authors disclosed patent-licensing ties | Jensen 2022: NR plus pterostilbene (1,000 mg plus 200 mg/day) in 32 adults aged 55 to 80 did not improve muscle stem-cell recruitment or recovery after induced muscle injury |
| Muscle in adults over 60 | A 2025 meta-analysis found no significant effect on muscle mass, grip or gait speed | Same review: not supportive; mixed results in special groups |
| Overall | A 2026 systematic review of 33 human studies: oral NR and NMN consistently raise NAD-related blood levels and are generally well tolerated, but functional and healthspan outcomes were heterogeneous and often null; clinical effectiveness for anti-aging is inconclusive | Same |
Two things to note. Rising NAD+ in blood is a marker, not a health outcome. And no head-to-head trial of NMN against NR appeared in our search, so any claim that one “beats” the other is not trial-based. The site’s NAD+ boosters guide covers the biology.
From our cost per study dose dataset (brand pages, 28 Sept 2026 (Double Wood, Jarrow, Renue By Science and Tru Niagen prices re-checked 29 Sept 2026, unchanged), USD, before tax and shipping):
| Product | Price | Trial dose used | Per month | Testing stated |
|---|---|---|---|---|
| Renue By Science SLC Enteric NMN 250 mg, 200 ct | $58.95 | 250 mg/day (Igarashi) | $8.84 | third-party tested, no certifier named (page showed sold out 29 Sept) |
| Jarrow Formulas NMN 300 mg, 30 tablets | $49.99 | 250 mg/day (Igarashi) | $41.66 | none stated |
| Double Wood NMN | $48.95 | 250 mg/day (Igarashi) | not calculated (bottle count unread) | ISO/IEC 17025 labs, self-stated |
| Tru Niagen 300 mg (NR), 30 | $49 | 2,000 mg/day (Dollerup) | $326.67 | Alkemist Labs, named |
NR trial doses are several times a label serving, which drives the price; that is a fact about the trial, not a target. Third-party testing claims without a named certifier are not counted as certification.
Ask a doctor first if you take prescription medicines, have cancer or a history of it, or have kidney or liver disease. Look for a named testing organisation and a certificate of analysis for the specific lot. See where NMN sits in the graded supplement ladder and the complete stack. For a non-supplement route to higher NAD+, see the sleep and zone 2 protocols.
Researched from PubMed abstract records (29 Sept 2026), regulations.gov docket metadata (checked 2 Oct 2026) and regulatory reporting by NPA and Venable; the letters’ full text and the regulations.gov documents could not be opened by our tools in this audit (403, and the API rate-limited), so the posting dates in the timeline are the docket metadata as read when the page was written, and the 29 Sept 2025 and 2 Dec 2025 dates were re-confirmed against NPA, National Law Review and PolicyCanary. Prices from brand pages on 28 Sept 2026. Grades are our judgement using the published rubric. We did not test any product. General information, not medical advice.
Yes, as a dietary supplement. The FDA concluded in September 2025 that NMN is not excluded from the definition of a dietary supplement, reversing a November 2022 position, and reinstated a company's notification acknowledgment in December 2025. Companies still have to meet new dietary ingredient notification requirements, and FDA does not approve supplements or their health claims.
No trial we found compares them head to head. Both raise NAD+ measures in blood. NMN trials showed nominal gains in gait speed and grip in older men and better walking distance in a middle-aged dose trial; NR showed no effect on glucose tolerance in men with obesity. A 2025 meta-analysis found neither improved muscle mass or function in adults over 60.
Trials of weeks to months found it well tolerated, but they were short and small. Long-term safety is not established. Ask your doctor, especially if you take medicines or have cancer, kidney or liver disease.
A direct NAD+ precursor that restores declining NAD+ levels with age
An alternative NAD+ precursor with more human trial data than NMN
A polyphenol that activates sirtuins (SIRT1)
A methyl donor that counteracts the methylation depletion caused by NMN/NR supplementation
No head-to-head trial; both raise blood NAD+, outcomes mixed
NAD+ precursors (NMN, NR) and IV NAD+ vs the human evidence: blood levels rise, functional results are mixed, IV NAD+ has no anti-aging outcome trials.
CoQ10 evidence: Q-SYMBIO in heart failure patients, mixed statin-muscle-pain meta-analyses, ubiquinol vs ubiquinone, and monthly cost at the trial dose.
Longevity supplements where the best human trials found no benefit: the claim, the strongest trial or review, the result and a grade for each.
Lithium orotate: a 2025 Nature study links brain lithium loss to Alzheimer's in mice and human tissue; no human supplement trial. NDGA not covered.
Berberine evidence: a meta-analysis of 46 trials in type 2 diabetes, how it compared with metformin in a small pilot, side effects, and what is unproven.